6 O
ADVERSE O
REACTIONS O
The O
following O
important O
adverse O
reactions O
are O
described O
below O
and O
elsewhere O
in O
labeling O
: O
* O
Serotonin B-OSE_Labeled_AE
Syndrome I-OSE_Labeled_AE
or O
NMS B-OSE_Labeled_AE
- I-OSE_Labeled_AE
like I-OSE_Labeled_AE
Reactions I-OSE_Labeled_AE
[ O
see O
Warnings O
and O
Precautions O
( O
5.1 O
) O
] O
* O
Valvular B-OSE_Labeled_AE
Heart I-OSE_Labeled_AE
Disease I-OSE_Labeled_AE
[ O
see O
Warnings O
and O
Precautions O
( O
5.2 O
) O
] O
* O
Cognitive B-OSE_Labeled_AE
Impairment I-OSE_Labeled_AE
[ O
see O
Warnings O
and O
Precautions O
( O
5.3 O
) O
] O
* O
Psychiatric B-OSE_Labeled_AE
Disorders I-OSE_Labeled_AE
[ O
see O
Warnings O
and O
Precautions O
( O
5.4 O
) O
] O
* O
Hypoglycemia B-OSE_Labeled_AE
[ O
see O
Warnings O
and O
Precautions O
( O
5.5 O
) O
] O
* O
Heart B-OSE_Labeled_AE
Rate I-OSE_Labeled_AE
Decreases I-OSE_Labeled_AE
[ O
see O
Warnings O
and O
Precautions O
( O
5.7 O
) O
] O
* O
Hematological B-OSE_Labeled_AE
Changes I-OSE_Labeled_AE
[ O
see O
Warnings O
and O
Precautions O
( O
5.8 O
) O
] O
* O
Prolactin B-OSE_Labeled_AE
Elevation I-OSE_Labeled_AE
[ O
see O
Warnings O
and O
Precautions O
( O
5.9 O
) O
] O
EXCERPT O
: O
Most O
common O
adverse O
reactions O
( O
greater O
than O
5 O
% O
) O
in O
non-diabetic O
patients O
are O
headache O
, O
dizziness O
, O
fatigue O
, O
nausea O
, O
dry O
mouth O
, O
and O
constipation O
, O
and O
in O
diabetic O
patients O
are O
hypoglycemia O
, O
headache O
, O
back O
pain O
, O
cough O
, O
and O
fatigue O
. O

( O
6.1 O
) O
To O
report O
SUSPECTED O
ADVERSE O
REACTIONS O
, O
contact O
Eisai O
Inc O
. O
at O
1-888-274-2378 O
or O
FDA O
at O
1-800-FDA-1088 O
or O
at O
www.fda.gov/medwatch O
. O

6.1 O
Clinical O
Trials O
Experience O
In O
the O
BELVIQ O
placebo-controlled O
clinical O
database O
of O
trials O
of O
at O
least O
one O
year O
in O
duration O
, O
of O
6888 O
patients O
( O
3451 O
BELVIQ O
vs O
. O
3437 O
placebo O
; O
age O
range O
18-66 O
years O
, O
79.3 O
% O
women O
, O
66.6 O
% O
Caucasians O
, O
19.2 O
% O
Blacks O
, O
11.8 O
% O
Hispanics O
, O
2.4 O
% O
other O
, O
7.4 O
% O
type O
2 O
diabetics B-Not_AE_Candidate
) O
, O
a O
total O
of O
1969 O
patients O
were O
exposed O
to O
BELVIQ O
10 O
mg O
twice O
daily O
for O
1 O
year O
and O
426 O
patients O
were O
exposed O
for O
2 O
years O
. O

In O
clinical O
trials O
of O
at O
least O
one O
year O
in O
duration O
, O
8.6 O
% O
of O
patients O
treated O
with O
BELVIQ O
prematurely O
discontinued O
treatment O
due O
to O
adverse O
reactions O
, O
compared O
with O
6.7 O
% O
of O
placebo-treated O
patients O
. O

The O
most O
common O
adverse O
reactions O
leading O
to O
discontinuation O
more O
often O
among O
BELVIQ O
treated O
patients O
than O
placebo O
were O
headache B-OSE_Labeled_AE
( O
1.3 O
% O
vs O
. O
0.8 O
% O
) O
, O
depression B-OSE_Labeled_AE
( O
0.9 O
% O
vs O
. O
0.5 O
% O
) O
and O
dizziness B-OSE_Labeled_AE
( O
0.7 O
% O
vs O
. O
0.2 O
% O
) O
. O

Most O
Common O
Adverse O
Reactions O
Because O
clinical O
trials O
are O
conducted O
under O
widely O
varying O
conditions O
, O
adverse O
reaction O
rates O
observed O
in O
the O
clinical O
trials O
of O
a O
drug O
can O
not O
be O
directly O
compared O
to O
rates O
in O
the O
clinical O
trials O
of O
another O
drug O
and O
may O
not O
reflect O
the O
rates O
observed O
in O
practice O
. O

The O
most O
common O
adverse O
reactions O
for O
non-diabetic O
patients O
( O
greater O
than O
5 O
% O
and O
more O
commonly O
than O
placebo O
) O
treated O
with O
BELVIQ O
compared O
to O
placebo O
were O
headache B-OSE_Labeled_AE
, O
dizziness B-OSE_Labeled_AE
, O
fatigue B-OSE_Labeled_AE
, O
nausea B-OSE_Labeled_AE
, O
dry B-OSE_Labeled_AE
mouth I-OSE_Labeled_AE
, O
and O
constipation B-OSE_Labeled_AE
. O

The O
most O
common O
adverse O
reactions O
for O
diabetic O
patients O
were O
hypoglycemia B-OSE_Labeled_AE
, O
headache B-OSE_Labeled_AE
, O
back B-OSE_Labeled_AE
pain I-OSE_Labeled_AE
, O
cough B-OSE_Labeled_AE
, O
and O
fatigue B-OSE_Labeled_AE
. O

Adverse O
reactions O
that O
were O
reported O
by O
greater O
than O
or O
equal O
to O
2 O
% O
of O
patients O
and O
were O
more O
frequently O
reported O
by O
patients O
taking O
BELVIQ O
compared O
to O
placebo O
are O
summarized O
in O
Table O
2 O
( O
non-diabetic O
subjects O
) O
and O
Table O
3 O
( O
subjects O
with O
type O
2 O
diabetes O
mellitus O
) O
. O

Table O
2 O
. O

Adverse O
Reactions O
Reported O
by O
Greater O
Than O
or O
Equal O
to O
2 O
% O
of O
BELVIQ O
Patients O
and O
More O
Commonly O
than O
with O
Placebo O
in O
Patients O
without O
Diabetes O
Mellitus O
Adverse O
Reaction O
Number O
of O
patients O
( O
% O
) O
BELVIQ O
10 O
mg O
BID O
N=3195 O
Placebo O
N=3185 O
Gastrointestinal B-NonOSE_AE
Disorders I-NonOSE_AE
Nausea B-OSE_Labeled_AE
264 O
( O
8.3 O
) O
170 O
( O
5.3 O
) O
Diarrhea B-OSE_Labeled_AE
207 O
( O
6.5 O
) O
179 O
( O
5.6 O
) O
Constipation B-OSE_Labeled_AE
186 O
( O
5.8 O
) O
125 O
( O
3.9 O
) O
Dry B-OSE_Labeled_AE
mouth I-OSE_Labeled_AE
169 O
( O
5.3 O
) O
74 O
( O
2.3 O
) O
Vomiting B-OSE_Labeled_AE
122 O
( O
3.8 O
) O
83 O
( O
2.6 O
) O
General B-NonOSE_AE
Disorders I-NonOSE_AE
And I-NonOSE_AE
Administration I-NonOSE_AE
Site I-NonOSE_AE
Conditions I-NonOSE_AE
Fatigue B-OSE_Labeled_AE
229 O
( O
7.2 O
) O
114 O
( O
3.6 O
) O
Infections B-NonOSE_AE
And O
Infestations O
Upper B-OSE_Labeled_AE
respiratory I-OSE_Labeled_AE
tract I-OSE_Labeled_AE
infection I-OSE_Labeled_AE
439 O
( O
13.7 O
) O
391 O
( O
12.3 O
) O
Nasopharyngitis B-OSE_Labeled_AE
414 O
( O
13.0 O
) O
381 O
( O
12.0 O
) O
Urinary B-OSE_Labeled_AE
tract I-OSE_Labeled_AE
infection I-OSE_Labeled_AE
207 O
( O
6.5 O
) O
171 O
( O
5.4 O
) O
Musculoskeletal B-NonOSE_AE
And O
Connective O
Tissue O
Disorders I-NonOSE_AE
Back B-OSE_Labeled_AE
pain I-OSE_Labeled_AE
201 O
( O
6.3 O
) O
178 O
( O
5.6 O
) O
Musculoskeletal B-OSE_Labeled_AE
pain I-OSE_Labeled_AE
65 O
( O
2.0 O
) O
43 O
( O
1.4 O
) O
Nervous B-NonOSE_AE
System I-NonOSE_AE
Disorders I-NonOSE_AE
Headache B-OSE_Labeled_AE
537 O
( O
16.8 O
) O
321 O
( O
10.1 O
) O
Dizziness B-OSE_Labeled_AE
270 O
( O
8.5 O
) O
122 O
( O
3.8 O
) O
Respiratory B-NonOSE_AE
, O
Thoracic O
And O
Mediastinal O
Disorders I-NonOSE_AE
Cough B-OSE_Labeled_AE
136 O
( O
4.3 O
) O
109 O
( O
3.4 O
) O
Oropharyngeal B-OSE_Labeled_AE
pain I-OSE_Labeled_AE
111 O
( O
3.5 O
) O
80 O
( O
2.5 O
) O
Sinus B-OSE_Labeled_AE
congestion I-OSE_Labeled_AE
93 O
( O
2.9 O
) O
78 O
( O
2.4 O
) O
Skin B-NonOSE_AE
And I-NonOSE_AE
Subcutaneous I-NonOSE_AE
Tissue I-NonOSE_AE
Disorders I-NonOSE_AE
Rash B-OSE_Labeled_AE
67 O
( O
2.1 O
) O
58 O
( O
1.8 O
) O
Table O
3 O
. O

Adverse O
Reactions O
Reported O
by O
Greater O
Than O
or O
Equal O
to O
2 O
% O
of O
BELVIQ O
Patients O
and O
More O
Commonly O
than O
with O
Placebo O
in O
Patients O
with O
Type O
2 O
Diabetes O
Mellitus O
Number O
of O
patients O
( O
% O
) O
Adverse O
Reaction O
BELVIQ O
10 O
mg O
BID O
N=256 O
Placebo O
N=252 O
Gastrointestinal B-NonOSE_AE
Disorders I-NonOSE_AE
Nausea B-OSE_Labeled_AE
24 O
( O
9.4 O
) O
20 O
( O
7.9 O
) O
Toothache B-OSE_Labeled_AE
7 O
( O
2.7 O
) O
0 O
General B-NonOSE_AE
Disorders I-NonOSE_AE
And I-NonOSE_AE
Administration I-NonOSE_AE
Site I-NonOSE_AE
Conditions I-NonOSE_AE
Fatigue B-OSE_Labeled_AE
19 O
( O
7.4 O
) O
10 O
( O
4.0 O
) O
Peripheral B-OSE_Labeled_AE
edema I-OSE_Labeled_AE
12 O
( O
4.7 O
) O
6 O
( O
2.4 O
) O
Immune B-NonOSE_AE
System I-NonOSE_AE
Disorders I-NonOSE_AE
Seasonal B-OSE_Labeled_AE
allergy I-OSE_Labeled_AE
8 O
( O
3.1 O
) O
2 O
( O
0.8 O
) O
Infections B-NonOSE_AE
And O
Infestations O
Nasopharyngitis B-OSE_Labeled_AE
29 O
( O
11.3 O
) O
25 O
( O
9.9 O
) O
Urinary B-OSE_Labeled_AE
tract I-OSE_Labeled_AE
infection I-OSE_Labeled_AE
23 O
( O
9.0 O
) O
15 O
( O
6.0 O
) O
Gastroenteritis B-OSE_Labeled_AE
8 O
( O
3.1 O
) O
5 O
( O
2.0 O
) O
Metabolism B-NonOSE_AE
And I-NonOSE_AE
Nutrition I-NonOSE_AE
Disorders I-NonOSE_AE
Hypoglycemia B-OSE_Labeled_AE
75 O
( O
29.3 O
) O
53 O
( O
21.0 O
) O
Worsening B-OSE_Labeled_AE
of I-OSE_Labeled_AE
diabetes I-OSE_Labeled_AE
mellitus I-OSE_Labeled_AE
7 O
( O
2.7 O
) O
2 O
( O
0.8 O
) O
Decreased B-OSE_Labeled_AE
appetite I-OSE_Labeled_AE
6 O
( O
2.3 O
) O
1 O
( O
0.4 O
) O
Musculoskeletal B-NonOSE_AE
And O
Connective O
Tissue O
Disorders I-NonOSE_AE
Back B-OSE_Labeled_AE
pain I-OSE_Labeled_AE
30 O
( O
11.7 O
) O
20 O
( O
7.9 O
) O
Muscle B-OSE_Labeled_AE
spasms I-OSE_Labeled_AE
12 O
( O
4.7 O
) O
9 O
( O
3.6 O
) O
Nervous B-NonOSE_AE
System I-NonOSE_AE
Disorders I-NonOSE_AE
Headache B-OSE_Labeled_AE
37 O
( O
14.5 O
) O
18 O
( O
7.1 O
) O
Dizziness B-OSE_Labeled_AE
18 O
( O
7.0 O
) O
16 O
( O
6.3 O
) O
Psychiatric B-NonOSE_AE
Disorders I-NonOSE_AE
Anxiety B-OSE_Labeled_AE
9 O
( O
3.5 O
) O
8 O
( O
3.2 O
) O
Insomnia B-OSE_Labeled_AE
9 O
( O
3.5 O
) O
6 O
( O
2.4 O
) O
Stress B-OSE_Labeled_AE
7 O
( O
2.7 O
) O
3 O
( O
1.2 O
) O
Depression B-OSE_Labeled_AE
6 O
( O
2.3 O
) O
5 O
( O
2.0 O
) O
Respiratory B-NonOSE_AE
, I-NonOSE_AE
Thoracic I-NonOSE_AE
And I-NonOSE_AE
Mediastinal I-NonOSE_AE
Disorders I-NonOSE_AE
Cough B-OSE_Labeled_AE
21 O
( O
8.2 O
) O
11 O
( O
4.4 O
) O
Vascular B-NonOSE_AE
Disorders I-NonOSE_AE
Hypertension B-OSE_Labeled_AE
13 O
( O
5.1 O
) O
8 O
( O
3.2 O
) O
Other O
Adverse O
Reactions O
Serotonin-associated O
Adverse O
Reactions O
SSRIs O
, O
SNRIs O
, O
bupropion O
, O
tricyclic O
antidepressants O
, O
and O
MAOIs O
were O
excluded O
from O
the O
BELVIQ O
trials O
. O

Triptans O
and O
dextromethorphan O
were O
permitted O
: O
2 O
% O
and O
15 O
% O
, O
respectively O
, O
of O
patients O
without O
diabetes O
and O
1 O
% O
and O
12 O
% O
, O
respectively O
, O
of O
patients O
with O
type O
2 O
diabetes O
experienced O
concomitant O
use O
at O
some O
point O
during O
the O
trials O
. O

Two O
patients O
treated O
with O
BELVIQ O
in O
the O
clinical O
program O
experienced O
a O
constellation O
of O
symptoms O
and O
signs O
consistent O
with O
serotonergic B-OSE_Labeled_AE
excess I-OSE_Labeled_AE
, O
including O
one O
patient O
on O
concomitant O
dextromethorphan O
who O
reported O
an O
event O
of O
serotonin B-NonOSE_AE
syndrome I-NonOSE_AE
. O

Some O
symptoms O
of O
possible O
serotonergic O
etiology O
that O
are O
included O
in O
the O
criteria O
for O
serotonin B-NonOSE_AE
syndrome I-NonOSE_AE
were O
reported O
by O
patients O
treated O
with O
BELVIQ O
and O
placebo O
during O
clinical O
trials O
of O
at O
least O
1 O
year O
in O
duration O
. O

In O
both O
groups O
, O
chills B-OSE_Labeled_AE
were O
the O
most O
frequent O
of O
these O
events O
( O
1.0 O
% O
vs O
. O
0.2 O
% O
, O
respectively O
) O
, O
followed O
by O
tremor B-OSE_Labeled_AE
( O
0.3 O
% O
vs O
. O
0.2 O
% O
) O
, O
confusional B-OSE_Labeled_AE
state I-OSE_Labeled_AE
( O
0.2 O
% O
vs O
. O
less O
than O
0.1 O
% O
) O
, O
disorientation B-OSE_Labeled_AE
( O
0.1 O
% O
vs O
. O
0.1 O
% O
) O
and O
hyperhidrosis B-OSE_Labeled_AE
( O
0.1 O
% O
vs O
. O
0.2 O
% O
) O
. O

Because O
serotonin B-NonOSE_AE
syndrome I-NonOSE_AE
has O
a O
very O
low O
incidence O
, O
an O
association O
between O
BELVIQ O
and O
serotonin B-NonOSE_AE
syndrome I-NonOSE_AE
can O
not O
be O
excluded O
on O
the O
basis O
of O
clinical O
trial O
results O
[ O
see O
Warnings O
and O
Precautions O
( O
5.1 O
) O
] O
. O

Hypoglycemia O
in O
Patients O
with O
Type O
2 O
Diabetes O
In O
a O
clinical O
trial O
of O
patients O
with O
type B-Not_AE_Candidate
2 I-Not_AE_Candidate
diabetes I-Not_AE_Candidate
mellitus I-Not_AE_Candidate
, O
hypoglycemia B-OSE_Labeled_AE
requiring O
the O
assistance O
of O
another O
person O
occurred O
in O
4 O
( O
1.6 O
% O
) O
of O
BELVIQ-treated O
patients O
and O
in O
1 O
( O
0.4 O
% O
) O
placebo-treated O
patient O
. O

Of O
these O
4 O
BELVIQ-treated O
patients O
, O
all O
were O
concomitantly O
using O
a O
sulfonylurea O
( O
with O
or O
without O
metformin O
) O
. O

BELVIQ O
has O
not O
been O
studied O
in O
patients O
taking O
insulin O
. O

Hypoglycemia B-OSE_Labeled_AE
defined O
as O
blood B-NonOSE_AE
sugar I-NonOSE_AE
less I-NonOSE_AE
than I-NonOSE_AE
or I-NonOSE_AE
equal I-NonOSE_AE
to I-NonOSE_AE
6 I-NonOSE_AE
5 I-NonOSE_AE
mg I-NonOSE_AE
/ I-NonOSE_AE
dL I-NonOSE_AE
and I-NonOSE_AE
with I-NonOSE_AE
symptoms I-NonOSE_AE
occurred O
in O
19 O
( O
7.4 O
% O
) O
BELVIQ-treated O
patients O
and O
16 O
( O
6.3 O
% O
) O
placebo-treated O
patients O
. O

Cognitive O
Impairment O
In O
clinical O
trials O
of O
at O
least O
1-year O
duration O
, O
adverse O
reactions O
related O
to O
cognitive B-OSE_Labeled_AE
impairment I-OSE_Labeled_AE
( O
e.g. O
, O
difficulty B-OSE_Labeled_AE
with I-OSE_Labeled_AE
concentration I-OSE_Labeled_AE
/attention O
, O
difficulty B-OSE_Labeled_AE
with I-OSE_Labeled_AE
memory I-OSE_Labeled_AE
, O
and O
confusion B-OSE_Labeled_AE
) O
occurred O
in O
2.3 O
% O
of O
patients O
taking O
BELVIQ O
and O
0.7 O
% O
of O
patients O
taking O
placebo O
. O

Psychiatric O
Disorders O
Psychiatric B-OSE_Labeled_AE
disorders I-OSE_Labeled_AE
leading O
to O
hospitalization O
or O
drug O
withdrawal O
occurred O
more O
frequently O
in O
patients O
treated O
with O
BELVIQ O
( O
2.2 O
% O
) O
as O
compared O
to O
placebo O
( O
1.1 O
% O
) O
in O
non-diabetic O
patients O
. O

Euphoria B-OSE_Labeled_AE
. O

In O
short-term O
studies O
with O
healthy O
individuals O
, O
the O
incidence O
of O
euphoric B-NonOSE_AE
mood I-NonOSE_AE
following O
supratherapeutic O
doses O
of O
BELVIQ O
( O
40 O
and O
60 O
mg O
) O
was O
increased O
as O
compared O
to O
placebo O
[ O
see O
Drug O
Abuse O
and O
Dependence O
( O
9.2 O
) O
] O
. O

In O
clinical O
trials O
of O
at O
least O
1-year O
duration O
in O
obese B-Not_AE_Candidate
patients O
, O
euphoria B-OSE_Labeled_AE
was O
observed O
in O
0.17 O
% O
of O
patients O
taking O
BELVIQ O
and O
0.03 O
% O
taking O
placebo O
. O

Depression B-OSE_Labeled_AE
and O
Suicidality B-OSE_Labeled_AE
. O

In O
trials O
of O
at O
least O
one O
year O
in O
duration O
, O
reports O
of O
depression B-OSE_Labeled_AE
/ O
mood B-OSE_Labeled_AE
problems I-OSE_Labeled_AE
occurred O
in O
2.6 O
% O
BELVIQ-treated O
vs O
. O
2.4 O
% O
placebo-treated O
and O
suicidal B-OSE_Labeled_AE
ideation I-OSE_Labeled_AE
occurred O
in O
0.6 O
% O
BELVIQ-treated O
vs O
. O
0.4 O
% O
placebo-treated O
patients O
. O

1.3 O
% O
of O
BELVIQ O
patients O
vs O
. O
0.6 O
% O
of O
placebo O
patients O
discontinued O
drug O
due O
to O
depression B-OSE_Labeled_AE
- O
, O
mood B-OSE_Labeled_AE
- I-OSE_Labeled_AE
, O
or O
suicidal O
ideation- O
related I-OSE_Label
ed B-OSE_Labeled_AE
_ I-OSE_Labeled_AE
AE I-OSE_Labeled_AE
events I-OSE_Labeled_AE
  I-OSE_Labeled_AE
I I-OSE_Labeled_AE
- I-OSE_Labeled_AE
OSE_Labeled_AE O
. O

Laboratory O
Abnormalities O
Lymphocyte O
and O
Neutrophil O
Counts O
. O

In O
clinical O
trials O
of O
at O
least O
1-year O
duration O
, O
lymphocyte B-OSE_Labeled_AE
counts I-OSE_Labeled_AE
were O
below I-OSE_Labeled_AE
the I-OSE_Labeled_AE
lower I-OSE_Labeled_AE
limit I-OSE_Labeled_AE
of I-OSE_Labeled_AE
normal I-OSE_Labeled_AE
in O
12.2 O
% O
of O
patients O
taking O
BELVIQ O
and O
9.0 O
% O
taking O
placebo O
, O
and O
neutrophil B-OSE_Labeled_AE
counts I-OSE_Labeled_AE
were I-OSE_Labeled_AE
low I-OSE_Labeled_AE
in O
5.6 O
% O
and O
4.3 O
% O
, O
respectively O
. O

Hemoglobin O
. O

In O
clinical O
trials O
of O
at O
least O
1-year O
duration O
, O
10.4 O
% O
of O
patients O
taking O
BELVIQ O
and O
9.3 O
% O
taking O
placebo O
had O
hemoglobin B-OSE_Labeled_AE
below I-OSE_Labeled_AE
the I-OSE_Labeled_AE
lower I-OSE_Labeled_AE
limit I-OSE_Labeled_AE
of I-OSE_Labeled_AE
normal I-OSE_Labeled_AE
at O
some O
point O
during O
the O
trials O
. O

Prolactin O
. O

In O
clinical O
trials O
, O
elevations B-OSE_Labeled_AE
of I-OSE_Labeled_AE
prolactin I-OSE_Labeled_AE
greater O
than O
the O
upper O
limit O
of O
normal O
, O
two O
times O
the O
upper O
limit O
of O
normal O
, O
and O
five O
times O
the O
upper O
limit O
of O
normal O
, O
occurred O
in O
6.7 O
% O
, O
1.7 O
% O
, O
and O
0.1 O
% O
of O
BELVIQ-treated O
patients O
and O
4.8 O
% O
, O
0.8 O
% O
, O
and O
0.0 O
% O
of O
placebo-treated O
patients O
, O
respectively O
. O

Eye O
disorders O
. O

More O
patients O
on O
BELVIQ O
reported O
an O
eye B-OSE_Labeled_AE
disorder I-OSE_Labeled_AE
than O
patients O
on O
placebo O
in O
clinical O
trials O
of O
patients O
without O
diabetes B-Not_AE_Candidate
( O
4.5 O
% O
vs O
. O
3.0 O
% O
) O
and O
with O
type B-Not_AE_Candidate
2 I-Not_AE_Candidate
diabetes I-Not_AE_Candidate
( O
6.3 O
% O
vs O
. O
1.6 O
% O
) O
. O

In O
the O
population O
without O
diabetes B-Not_AE_Candidate
, O
events O
of O
blurred B-OSE_Labeled_AE
vision I-OSE_Labeled_AE
, O
dry B-OSE_Labeled_AE
eye I-OSE_Labeled_AE
, O
and O
visual B-OSE_Labeled_AE
impairment I-OSE_Labeled_AE
occurred O
in O
BELVIQ-treated O
patients O
at O
an O
incidence O
greater O
than O
that O
of O
placebo O
. O

In O
the O
population O
with O
type B-Not_AE_Candidate
2 I-Not_AE_Candidate
diabetes I-Not_AE_Candidate
, O
visual B-OSE_Labeled_AE
disorders I-OSE_Labeled_AE
, O
conjunctival B-OSE_Labeled_AE
infections I-OSE_Labeled_AE
, O
irritations O
, O
and O
inflammations O
, O
ocular B-OSE_Labeled_AE
sensation I-OSE_Labeled_AE
disorders I-OSE_Labeled_AE
, O
and O
cataract B-OSE_Labeled_AE
conditions I-OSE_Labeled_AE
occurred O
in O
BELVIQ-treated O
patients O
at O
an O
incidence O
greater O
than O
placebo O
. O

Echocardiographic O
Safety O
Assessments O
The O
possible O
occurrence O
of O
regurgitant B-NonOSE_AE
cardiac I-NonOSE_AE
valve I-NonOSE_AE
disease I-NonOSE_AE
was O
prospectively O
evaluated O
in O
7794 O
patients O
in O
three O
clinical O
trials O
of O
at O
least O
one O
year O
in O
duration O
, O
3451 O
of O
whom O
took O
BELVIQ O
10 O
mg O
twice O
daily O
. O

The O
primary O
echocardiographic O
safety O
parameter O
was O
the O
proportion O
of O
patients O
who O
developed O
echocardiographic O
criteria O
of O
mild O
or O
greater O
aortic B-NonOSE_AE
insufficiency I-NonOSE_AE
and/or O
moderate O
or O
greater O
mitral B-NonOSE_AE
insufficiency I-NonOSE_AE
from O
baseline O
to O
1 O
year O
. O

At O
1 O
year O
, O
2.4 O
% O
of O
patients O
who O
received O
BELVIQ O
and O
2.0 O
% O
of O
patients O
who O
received O
placebo O
developed O
valvular B-OSE_Labeled_AE
regurgitation I-OSE_Labeled_AE
. O

The O
relative O
risk O
for O
valvulopathy B-OSE_Labeled_AE
with O
BELVIQ O
is O
summarized O
in O
Table O
4 O
. O

BELVIQ O
was O
not O
studied O
in O
patients O
with O
congestive B-Not_AE_Candidate
heart I-Not_AE_Candidate
failure I-Not_AE_Candidate
or O
hemodynamically-significant O
valvular B-Not_AE_Candidate
heart I-Not_AE_Candidate
disease I-Not_AE_Candidate
[ O
see O
Warnings O
and O
Precautions O
( O
5.2 O
) O
] O
. O

Table O
4 O
. O

Incidence O
of O
FDA-Defined O
Valvulopathy O
at O
Week O
52 O
by O
Treatment O
Group1 O
1 O
Patients O
without O
valvulopathy O
at O
baseline O
who O
received O
study O
medication O
and O
had O
a O
post-baseline O
echocardiogram O
; O
ITT-intention-to-treat O
; O
LOCF-last O
observation O
carried O
forward O
Study O
1 O
Study O
2 O
Study O
3 O
BELVIQ O
N=1278 O
Placebo O
N=1191 O
BELVIQ O
N=1208 O
Placebo O
N=1153 O
BELVIQ O
N=210 O
Placebo O
N=209 O
FDA-defined O
Valvulopathy B-OSE_Labeled_AE
, O
n O
( O
% O
) O
34 O
( O
2.7 O
) O
28 O
( O
2.4 O
) O
24 O
( O
2.0 O
) O
23 O
( O
2.0 O
) O
6 O
( O
2.9 O
) O
1 O
( O
0.5 O
) O
Relative O
Risk O
( O
95 O
% O
CI O
) O
1.13 O
( O
0.69 O
, O
1.85 O
) O
1.00 O
( O
0.57 O
, O
1.75 O
) O
5.97 O
( O
0.73 O
, O
49.17 O
) O
Pooled O
RR O
( O
95 O
% O
CI O
) O
1.16 O
( O
0.81 O
, O
1.67 O
) O

